Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Womens HealthAWHL 38 Debt-to-EBITDA is 1.13 as of Mar. 2026. GuruFocus rates AWHL with a GF Score™ of 38/100 and a GF Value™ of $0.28 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, Aspira Womens Health ranks worse than 877192.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Aspira Womens Health's Debt-to-EBITDA or its related term are showing as below:
AWHL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.47 Med: -0.15 Max: -0.11
Current: -0.47
During the past 13 years, the highest Debt-to-EBITDA Ratio of Aspira Womens Health was -0.11. The lowest was -0.47. And the median was -0.15.
AWHL's Debt-to-EBITDA is ranked worse than 100% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs AWHL: -0.47
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Aspira Womens Health Debt-to-EBITDA Related Terms
Aspira Womens Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AWHL vs MDXH, QUCY, XWEL: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Aspira Womens Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Aspira Womens Health (AWHL) has a Debt-to-EBITDA of 1.13 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aspira Womens Health. According to the industry distribution chart, Aspira Womens Health ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry.
Is Aspira Womens Health's Debt-to-EBITDA too high?
Aspira Womens Health's current Debt-to-EBITDA is 1.13. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. Aspira Womens Health's value of 1.13 is 51.1% below this industry median. Based on the distribution chart, Aspira Womens Health ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Aspira Womens Health has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Debt-to-EBITDA compare to MDXH and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #999999 out of 114 companies for Debt-to-EBITDA. This places Aspira Womens Health in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. Aspira Womens Health's value of 1.13 is 51.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Womens Health's current Debt-to-EBITDA of 1.13 is 51.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aspira Womens Health. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current Debt-to-EBITDA is 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.36 — trading 28.5% above its estimated fair value. The current Debt-to-EBITDA is 1.13 and 51.1% below the Medical Diagnostics & Research industry median of 2.31. Aspira Womens Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Debt-to-EBITDA is 1.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.36 is trading 28.5% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Modestly Overvalued.
Key valuation signals for AWHL:
Debt-to-EBITDA: 1.13
GF Value™: $0.28 vs. price of $0.36 (28.5% above fair value)
Industry Position: 51.1% below the Medical Diagnostics & Research median (#999999 of 114)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
38GF Score
Get the complete analysis for AWHL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
